Liver Cancer Therapeutics Market Size Report 2032 | Bayer, Hoffmann-La Roche, Kowa Company Ltd., Sirtex Medical, Bracco Diagnostics Inc., Light Sciences Oncology, MediGene, Pfizer

DelveInsight's "Liver Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Liver Cancer, historical and forecasted epidemiology as well as the Liver Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Liver Cancer Market with DelveInsight's In-Depth Report @ Liver Cancer Market Size- https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Liver Cancer Market Report
• In February 2025:- Roswell Park Cancer Institute:- This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
• In February 2025:- Eisai Inc.:- The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
• In February 2025:-University of Texas Southwestern Medical Center:- The study is an open-label, non-randomized, phase II basket therapeutic clinical trial. To determine the objective response rate of combination ligufalimab and cadonilimab in refractory and advanced hepatocellular carcinoma and biliary tract cancers.
• In February 2025:- Hoffmann-La Roche:- This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
• According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of liver cancer and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 new diagnosed cases in 2021 and the mortality rate was 6.6 per 100,000 per year and the 5-year survival rate was 20.3%. Of them, the stage wise incident cases of liver cancer and intrahepatic bile duct cancer were Localized (45%), Regional (26%), Distant (18%), and Unknown (11%).
• The leading Liver Cancer Companies such as Bayer, Hoffmann-La Roche, Kowa Company Ltd., Sirtex Medical, Bracco Diagnostics Inc., Light Sciences Oncology, MediGene, Pfizer, and others.
• Promising Liver Cancer Therapies such as Pembrolizumab, Atezolizumab, Tiragolumab, Bevacizumab 15 mg/kg, NIK-333(peretinoin), Sorafenib and others.

Stay ahead in the Liver Cancer Therapeutics Market with DelveInsight's Strategic Report @ Liver Cancer Market Outlook- https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cancer Epidemiology Segmentation in the 7MM
• Total Liver Cancer Incident Cases
• Liver Cancer Stage-wise Patients
• Total Liver Cancer Treated Cases

Download the report to understand which factors are driving Liver Cancer epidemiology trends @ Liver Cancer Prevalence- https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cancer Marketed Drugs
• CYRAMZA (ramucirumabis): Eli Lilly
It is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells.

• KEYTRUDA (pembrolizumab): Merck
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with advanced liver cancer, including those with high microsatellite instability (MSI-H), DNA mismatch repair deficiency (dMMR), or high tumor mutational burden (TMB-H).

• TECENTRIQ (atezolizumab): Genetech
It is a checkpoint inhibitor that targets the PD-L1 pathway; approved, in combination with bevacizumab, as a first-line treatment for subsets of patients with advanced liver cancer.

• JEMPERLI (dostarlimab): GlaxoSmithKline
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with Liver Cancerthat has DNA mismatch repair deficiency (dMMR).

• OPDIVO (nivolumab): Bristol-Myers Squibb
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with advanced liver cancer, including in combination with ipilimumab.

• YERVOY (ipilimumab): Bristol-Myers Squibb
It is a checkpoint inhibitor that targets the CTLA-4 pathway; approved, in combination with nivolumab, for patients with advanced, previously treated liver cancer.

Liver Cancer Emerging Drugs
• H3B-6527, being developed by H3 Biomedicine, is a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC). The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for rare diseases or conditions that affect fewer than 200,000 people in the U.S. The orphan drug designation provides H3 Biomedicine with certain benefits, including market exclusivity upon regulatory approval is received, exemption of FDA application fees, and tax credits for qualified clinical trials.
• GNS561, being developed by Genoscience Pharma. is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent build-up of enlarged lysosomes by interacting with the palmitoyl-protein thioesterase 1 (PPT1).
• SAR445256 (known also as Alomfilimab, and formerly as KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Being developed by Kymab in collaboration with Sanofi, it is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells.
• Cabozantinib, being developed by Exelixis, is a targeted agent that inhibits the activity of receptor tyrosine kinases including MET, AXL, VEGF receptors and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors (ICIs).

Get In-Depth Knowledge on Liver Cancer Market Trends and Forecasts with DelveInsight @ Liver Cancer Treatment Market- https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cancer Market Outlook
There are currently six FDA-approved immunotherapy options for liver cancer. Several other immunotherapies are currently being tested in liver cancer clinical trial, including oncolytic viruses and adoptive cell therapy. Hence, the therapy market also include AVASTIN (bevacizumab) a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for subsets of patients with advanced liver cancer.

Liver Cancer Market Dynamics
The dynamics of the Liver Cancer market is anticipated to change in the coming years owing to increased Research and Development activities and increased patient pool. Key players such as H3 Biomedicine, Genoscience Pharma, Kymab, Sanofi, Exelixis and various others are involved in developing therapies for Liver Cancer.

Unlock Strategic Insights with DelveInsight's Comprehensive Liver Cancer Market Report @ Liver Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Liver Cancer Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Liver Cancer Companies- Bayer, Hoffmann-La Roche, Kowa Company Ltd., Sirtex Medical, Bracco Diagnostics Inc., Light Sciences Oncology, MediGene, Pfizer, and others.
• Liver Cancer Therapies- Pembrolizumab, Atezolizumab, Tiragolumab, Bevacizumab 15 mg/kg, NIK-333(peretinoin), Sorafenib and others.
• Liver Cancer Market Dynamics: Liver Cancer Market Drivers and Barriers
• Liver Cancer Market Access and Reimbursement and Unmet Needs

Table of Content
1. Report Introduction
2. Executive Summary
3. Liver Cancer Market Overview at a Glance
4. Disease Background and Overview: Liver Cancer
5. Case Reports
6. Epidemiology Methodology
7. Epidemiology and Patient Population
8. Liver Cancer: Country-Wise Epidemiology
9. Treatments & Medical Practices
10. Marketed Drugs
11. Emerging Therapies
12. Liver Cancer Market Size
14. SWOT Analysis
15. Market Access and Reimbursement
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.